Horizon Therapeutics plc: Sustained Patient Response to KRYSTEXXA (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial

-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging

Related Keywords

Alaska ,United States ,Ireland ,Amanda Phraner ,Clin Rheumatol ,Tina Ventura ,Johnk Botson ,Ada Kumar ,Ray Gordon ,Erin Linnihan ,Instagram ,Energy Computed Tomography ,Product Communications ,Patients With Uncontrolled Gout Co ,Linkedin ,American College Of Rheumatology Convergence ,Twitter ,Nasdaq ,Exchange Commission ,Gout Patients Using Dual Energy Computed Tomography ,Alaska Rheumatology Alliance ,Facebook ,American College ,Rheumatology Convergence ,Orthopedic Physicians ,Safety Study ,Increase Response Rates ,Receiving Pegloticase ,Monosodium Urate Crystal Deposit Volume During ,Patients Treated ,Pegloticase Plus Methotrexate Co Therapy ,Serial Dual Energy Computed Tomography ,Mount Sinai Hospital ,Urate Deposition ,Positron Emission Tomography Pre ,Post Pegloticase ,Uncontrolled Gout Receiving ,Heart Failure ,Full Prescribing Information ,Combination With Methotrexate ,Patients With Uncontrolled Gout ,Open Label Study ,Pegloticase Response ,Proof Of Concept Case ,Randomized Placebo Controlled Study ,Primary Efficacy ,Accepted Author ,Vice President ,Chief Investor Relations Officer ,Investor Relations ,Media Contact ,Horizon ,Herapeutics ,Sustained ,Patient ,Response ,Krystexxa ,Egloticase ,Injection ,Ethotrexate ,Ompared ,Alone ,Hown ,Through ,Month ,Mirror ,Randomized ,Ontrolled ,Trial ,